links.lww.com/MENO/A394

(1)

Supplementary File11. Proportion of hormone therapy use stratified by drug type, administration route and dose in the breast cancer sub-population

Supplementary Table15. Hormone therapy use stratified by drug type, administration route and dose in the breast cancer sub-population from 1996/1997 to 2014/2015

Number of women (%) Drug

type

Administr ation route

Dose 1996/19

97 1998/19

99 2000/20

01 2002/20

03 2004/20

05 2006/20

07 2008/20

09 2010/20

11 2012/20

13 2014/20 15 EPT^a oral low 23 (0.12) 29 (0.13) 45 (0.17) 62 (0.20) 52 (0.15) 51 (0.13) 62 (0.15) 62 (0.15) 55 (0.13) 41 (0.11)

normal 426

(2.21) 556

(2.43) 656

(2.45) 709

(2.31) 420

(1.21) 281

(0.74) 232

(0.58) 189

(0.46) 176

(0.43) 124

(0.33) mixed 20 (0.10) 14 (0.06) 27 (0.10) 24 (0.08) 24 (0.07) 41 (0.11) 28 (0.07) 18 (0.04) 21 (0.05) 16 (0.04) transderm

al

low N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b

normal 43 (0.22) 59 (0.26) 61 (0.23) 81 (0.26) 54 (0.16) 38 (0.10) 36 (0.09) 38 (0.09) 36 (0.09) 32 (0.08) mixed N/A^b N/A^b N/A^b N/A^b N/A^b 5 (0.01) N/A^b N/A^b N/A^b N/A^b

vaginal low N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b

normal N/A^b 5 (0.02) 6 (0.02) 5 (0.02) N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b mixed N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b other HT^c/

mixed use

low N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b 5 (0.01)

normal 36 (0.19) 47 (0.21) 45 (0.17) 45 (0.15) 18 (0.05) 18 (0.05) 13 (0.03) 11 (0.03) 13 (0.03) 9 (0.02) mixed 17 (0.09) 12 (0.05) 14 (0.05) 16 (0.05) 9 (0.03) 21 (0.05) 14 (0.03) 16 (0.04) 18 (0.04) 9 (0.02) ET^d oral low 25 (0.13) 30 (0.13) 58 (0.22) 64 (0.21) 58 (0.13) 49 (0.13) 49 (0.12) 56 (0.14) 62 (0.15) 33 (0.09)

normal 203

(1.06) 231

(1.01) 265

(0.99) 301

(0.98) 191

(0.38) 145

(0.38) 113

(0.28) 86 (0.21) 86 (0.21) 36 (0.10) mixed 6 (0.03) 6 (0.03) 6 (0.02) 9 (0.03) 14 (0.04) 17 (0.04) 8 (0.02) 6 (0.01) 8 (0.02) 11 (0.03) transderm

al

low 21 (0.11) 20 (0.09) 24 (0.09) 33 (0.11) 25 (0.07) 30 (0.08) 28 (0.07) 26 (0.06) 31 (0.08) 22 (0.06) normal 120

(0.62) 142

(0.62) 169

(0.63) 166

(0.54) 126

(0.36) 111

(0.29) 98 (0.24) 68 (0.16) 75 (0.18) 72 (0.19) mixed 10 (0.05) 10 (0.05) 13 (0.05) 12 (0.04) 19 (0.05) 9 (0.02) 7 (0.02) 6 (0.01) 10 (0.02) 6 (0.02) vaginal low 79 (0.41) 125

(0.55) 200

(0.75) 264

(0.86) 338

(0.97) 457

(1.20) 538

(1.34) 634

(1.53) 644

(1.56) 612

(1.62) normal 448

(2.33) 518

(2.26) 563

(2.10) 618

(2.01) 712

(2.05) 762

(1.99) 756

(1.88) 671

(1.62) 632

(1.53) 470

(1.24) mixed 28 (0.15) 23 (2.26) 37 (0.14) 50 (0.16) 55 (0.16) 62 (0.16) 86 (0.21) 97 (0.23) 102

(0.25) 90 (0.24) other HT^c/

mixed use

low N/A^b N/A^b N/A^b N/A^b 5 (0.01) N/A^b 5 (0.01) N/A^b N/A^b N/A^b

normal 32 (0.17) 31 (0.14) 29 (0.11) 31 (0.10) 20 (0.06) 14 (0.04) 13 (0.03) 8 (0.02) 9 (0.02) 7 (0.02) mixed 12 (0.06) 14 (0.06) 13 (0.05) 21 (0.07) 20 (0.06) 20 (0.05) 12 (0.03) 13 (0.03) 14 (0.03) 8 (0.02) tibolone oral low N/A^b N/A^b 5 (0.02) 5 (0.02) N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b

(2)

and mixed use

normal 14 (0.07) 13 (0.06) 26 (0.10) 31 (0.10) 10 (0.03) 8 (0.02) 7 (0.02) N/A^b N/A^b N/A^b mixed 61 (0.32) 90 (0.39) 159

(0.59) 203

(0.66) 187

(0.54) 136

(0.36) 94 (0.23) 81 (0.20) 56

(0.14 ) 31 (0.08) transderm

al

low N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b

normal N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b mixed N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b

vaginal low N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b

normal N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b mixed N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b other HT^c/

mixed use

low N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b 7 (0.02) N/A^b

normal 6 (0.03) 15 (0.07) 17 (0.06) 15 (0.05) 9 (0.03) N/A^b N/A^b N/A^b N/A^b N/A^b mixed N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b N/A^b

a

EPT: estrogen plus progestogen therapy

b

N/A: not applicable as cell counts <5 are not reportable due to Medicines and Healthcare products Regulatory Agency (MHRA) regulations

c

other HT: other hormone therapy use includes includes injections, implants, and nasal administrations

d

ET: estrogen therapy

(3)

Supplementary Figure17. Selected proportions of hormone therapy use stratified by drug type, administration route and dose in the breast cancer sub-population

a

EPT: estrogen plus progestogen therapy

b